Ask your clinician for the panel first — it is the cheaper, standardised measurement, and non-HDL cholesterol from it already captures most of what ApoB adds. Order ApoB when the two are likely to disagree: diabetes, obesity, high triglycerides, or a normal LDL on treatment. A mailed finger-stick ApoB is a screening band, not a venous result. We sell one of these and still say that.
| Compared on | ApoB test | Standard lipid panel |
|---|---|---|
| Evidence grade | Measurement tool | Not sold here Magellan sells no lipid panel, which is precisely why we can tell you when it is enough. |
| What it is | Apolipoprotein B (apoB) is the primary structural protein of the atherogenic lipoproteins, with exactly one apoB molecule carried on each particle of low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), intermediate-density lipoprotein, chylomicron remnants and lipoprotein(a). | The routine total cholesterol, LDL-C, HDL-C and triglyceride measurement, from which non-HDL cholesterol is calculated. Ordered and interpreted by a clinician. |
| Best human evidence | “In a meta-analysis of 233,455 people, apoB was the strongest lipid risk marker (relative-risk ratio 1.43 vs 1.34 for non-HDL-C and 1.25 for LDL-C), beating LDL-C by 12%.” Circulation. Cardiovascular quality and outcomes 2011 · PMID 21487090 | “Non-HDL-C and the ratio of total cholesterol to HDL-C were as good as or better than apolipoprotein fractions in the prediction of future cardiovascular events.” JAMA 2005 · PMID 16030277 |
| Dose / protocol studied | Once to find out where you stand, then repeat about 8-12 weeks after any deliberate change - a statin, a real diet change, meaningful weight loss. Fasting is not required for ApoB. Stick to one lab, because between-lab differences are larger than the changes you are looking for. | Standard practice for adult lipid screening; repeat interval is a clinical decision, not a consumer one. |
| Cost per test | $79.00 | Ordered by your clinician |
| Who it suits | Someone with diabetes, obesity, high triglycerides, or an LDL that looks fine on treatment — the situations where particle count and cholesterol mass diverge. | Almost everyone, as the first measurement. It is standardised, interpretable, and comes with someone qualified to act on it. |
| Who should skip it | Someone who has never had a standard panel. Start there; ApoB refines a risk picture, it does not create one. | Nobody, really — the question is whether you additionally need ApoB, not whether you need this. |
| Key caveat | ApoB counts atherogenic particles rather than the cholesterol inside them, and where the two disagree the particle count is the better guide to risk - that part is well supported and is why several lipid guidelines now list it as a preferred target. Whether a mailed finger-stick delivers that number reliably is a separate question, and the honest answer is partly. | LDL-C is an estimate of the cholesterol carried by atherogenic particles rather than a count of them, and it under-reads risk in people with diabetes, obesity or high triglycerides. Guidelines still treat LDL-C as the primary target and do not yet recommend routine ApoB screening for everyone. |
Prices are the typical listed prices in our catalog, not live Amazon prices, and a true cost-per-studied-dose is not shown because our catalog does not record servings per container — we would have to guess, so we don't.
ApoB counts atherogenic particles; a standard panel measures the cholesterol inside them. Most of the time they agree — and the interesting cases are the ones where they don't.
The standard panel. It is the standardised, interpretable measurement, and it comes with a clinician. ApoB refines an existing risk picture rather than replacing the first one.
ApoB adds real information. These are the discordance states, where particle number and cholesterol mass diverge. A 2024 National Lipid Association expert consensus recommends measuring ApoB to refine risk in exactly these situations.
ApoB. In residual-risk analyses, 64% of statin users were at goal for LDL-C and 63% for non-HDL-C, but only 52% were at goal for ApoB. That gap is the residual risk the panel alone does not show you.
Non-HDL cholesterol, from the panel you already have. A JAMA analysis in women found non-HDL cholesterol and the total-to-HDL ratio were as good as or better than apolipoprotein fractions for predicting future cardiovascular events. It costs nothing extra — it is arithmetic on a panel you already paid for.
A dried-blood-spot ApoB assay has been shown to correlate closely with a plasma reference method — but that work used laboratory-prepared spots from venous blood with a haematocrit correction applied, not cards collected at a kitchen table and posted in summer. Collection technique, spot volume and haematocrit are real sources of error nobody is controlling at your end.
Treat a home ApoB as a screening number that tells you roughly which band you are in. If it lands high, the next step is a venous panel through a clinician, not a second kit.
Each quote below is taken verbatim from the cited paper. Null and negative results are included on purpose — they are the reason a grade means anything.
“In a meta-analysis of 233,455 people, apoB was the strongest lipid risk marker (relative-risk ratio 1.43 vs 1.34 for non-HDL-C and 1.25 for LDL-C), beating LDL-C by 12%.”
“In multivariable MR, only apolipoprotein B (OR 1.92; 95% CI: 1.31-2.81; P < 0.001) retained a robust effect, with the estimate for LDL cholesterol (OR 0.85; 95% CI: 0.57-1.27; P = 0.44) reversing and that of triglycerides (OR 1.12; 95% CI: 1.02-1.23; P = 0.01) becoming weaker.”
“National Lipid Association expert consensus recommends apoB measurement to refine cardiovascular risk, especially in people with diabetes, obesity, high triglycerides or discordant LDL-C.”
“Non-HDL-C and the ratio of total cholesterol to HDL-C were as good as or better than apolipoprotein fractions in the prediction of future cardiovascular events.”
“non-HDL-cholesterol and apoB are superior to LDL-cholesterol in predicting cardiovascular risk”
“By contrast, a meta-analysis of published prospective studies demonstrated that non-HDL-C was superior to LDL-C, and apoB was superior to non-HDL-C.”
Magellan does not sell this option — which is exactly why we can compare it honestly.
Links go to an Amazon search for the product name, not to a specific listing, so you can compare sellers, price and third-party testing yourself.
As a risk marker, the evidence says yes: in a meta-analysis of 233,455 people ApoB was the strongest lipid risk marker, beating LDL-C by about 12%, and in Mendelian randomization only ApoB retained a robust effect. Guidelines still treat LDL-C as the primary treatment target.
Usually not, unless you have diabetes, obesity, high triglycerides, or a normal LDL while on treatment. Those are the discordance situations where ApoB changes the picture.
For many people, yes. Non-HDL cholesterol is superior to LDL-C and is calculated free from a standard panel, and one JAMA analysis in women found it as good as or better than apolipoprotein fractions. ApoB adds most where discordance is likely.
No. Fasting is not required for ApoB. Stick to one laboratory for repeat measurements, because between-lab differences can be larger than the change you are looking for.
If you don't have diabetes, probably neither. The 25-trial meta-analysis of CGM as a behaviour-change tool…
Home cuff for almost everyone. Both measure out-of-office pressure, which predicts outcomes better than a…
Oura, if the number is what matters. Against an ECG reference across 536 nights the Gen 4 gave nocturnal…